True Diagnostics has received the State Food and Drug Administration (SFDA) approval for its TrueDX Platform with its test for TSH.
The TrueDX Platform is portable and utilizes lateral flow immunoassay (LFIA) technology and provides quantitative results.
TrueDX Platform uses a finger prick of blood, small urine or saliva sample, toxins, surface bacteria, and measure the severity of any medical condition and provide results in minutes.
True Diagnostics president and CEO Jerry Lee said they also expect to make an announcement soon concerning a distribution partnership which clarifies how they are entering the China market with their new TrueDX Platform with TSH tests.